StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report issued on Sunday. The brokerage issued a sell rating on the stock.

CTLT has been the subject of a number of other reports. Barclays raised their target price on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. Stephens reissued an equal weight rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and a consensus target price of $55.65.

Catalent Stock Performance

Shares of CTLT opened at $56.51 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of -9.26 and a beta of 1.16. The stock has a 50 day moving average of $55.58 and a 200 day moving average of $54.18. Catalent has a 12 month low of $31.80 and a 12 month high of $60.20.

Catalent (NYSE:CTLT) last released its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. As a group, sell-side analysts forecast that Catalent will post -0.17 earnings per share for the current year.

Insider Activity at Catalent

In related news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalent

Large investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the last quarter. GAMMA Investing LLC lifted its stake in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the last quarter. Czech National Bank lifted its stake in Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares during the last quarter. BNP Paribas Asset Management Holding S.A. lifted its stake in Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock worth $802,000 after purchasing an additional 328 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in Catalent by 6.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock worth $256,000 after purchasing an additional 331 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.